Jain S, Saxena S, Kumar A (2014) Epidemiology of prostate cancer in India. Meta Gene 2:596–605
Article PubMed PubMed Central Google Scholar
Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10:63–89
Article CAS PubMed PubMed Central Google Scholar
Litwin MS, Tan HJ (2017) The diagnosis and treatment of prostate cancer: a review. JAMA J Am Med Assoc 317:2532–2542
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386:1132–1142
Article CAS PubMed PubMed Central Google Scholar
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 399:1695–1707
Article CAS PubMed Google Scholar
Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A (2010) Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562
Article CAS PubMed PubMed Central Google Scholar
Chen L, Zhou L, Wang C, Han Y, Lu Y, Liu J, Hu X, Yao T, Lin Y, Liang S, Shi S, Dong C (2019) Tumor-targeted drug and CpG delivery system for phototherapy and docetaxel-enhanced immunotherapy with polarization toward M1-type macrophages on triple negative breast cancers. Adv Mater 31:1904997
Rafiei P, Haddadi A (2017) Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. Int J Nanomedicine 12:935
Article CAS PubMed PubMed Central Google Scholar
About the influence of PEG spacers on the cytotoxicity of titanate nanotubes-docetaxel nanohybrids against a prostate cancer cell line.pdf
Dai L, Wei D, Zhang J, Shen T, Zhao Y, Liang J, Ma W, Zhang L, Liu Q, Zheng Y (2021) Aptamer-conjugated mesoporous polydopamine for docetaxel targeted delivery and synergistic photothermal therapy of prostate cancer. Cell Prolif 54:e13130
Article CAS PubMed PubMed Central Google Scholar
Dong Z, Wang Y, Guo J, Tian C, Pan W, Wang H, Yan J (2022) Prostate cancer therapy using docetaxel and formononetin combination: hyaluronic acid and epidermal growth factor receptor targeted peptide dual ligands modified binary nanoparticles to facilitate the in vivo anti-tumor activity. Drug Des Dev Ther 16:2683–2693
Wang WP, Iigo M, Sato J, Sekine K, Adachi I, Tsuda H (2000) Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin. Jpn J Cancer Res 91:1022
Article CAS PubMed PubMed Central Google Scholar
Asian Pacific Journal of Cancer Prevention [online]. http://journal.waocp.org/?sid=Entrez:PubMed&id=pmid:12716300&key=2000.1.4.277 (Accessed 10 Sep 2022)
Bermudez LE, Martinez-Zaguilán R, Filleur S, Perez-Zoghbi J (2010) V-ATPase at the cell surface in highly metastatic prostate cancer Cells [online]. https://ttu-ir.tdl.org/handle/2346/ETD-TTU-2010-12-1286 (Accessed 10 Sep 2022)
Guedes JP, Pereira CS, Rodrigues LR, Côrte-Real M (2018) Bovine milk lactoferrin selectively kills highly metastatic prostate cancer PC-3 and osteosarcoma MG-63 cells in vitro. Front Oncol 8:200
Article PubMed PubMed Central Google Scholar
Zhao Q, Cheng Y, Xiong Y (2021) LTF regulates the immune microenvironment of prostate cancer through JAK/STAT3 pathway. Front Oncol 11:1–12
Kondapi AK (2020) Targeting cancer with lactoferrin nanoparticles: recent advances. Nanomedicine. https://doi.org/10.2217/nnm-2020-0090.15,2071-2083
Elzoghby AO, Abdelmoneem MA, Hassanin IA, Abd Elwakil MM, Elnaggar MA, Mokhtar S, Fang JY, Elkhodairy KA (2020) Lactoferrin, a multi-functional glycoprotein: active therapeutic, drug nanocarrier and targeting ligand. Biomaterials 263:120355
Article CAS PubMed PubMed Central Google Scholar
Almowalad J, Somani S, Laskar P, Meewan J, Tate RJ, Mullin M, Dufès C (2021) Lactoferrin-bearing gold nanocages for gene delivery in prostate cancer cells in vitro. Int J Nanomedicine 16:4391–4407
Article PubMed PubMed Central Google Scholar
Almowalad J, Laskar P, Somani S, Meewan J, Tate RJ, Dufès C (2022) Lactoferrin- and dendrimer-bearing gold nanocages for stimulus-free DNA delivery to prostate cancer cells. Int J Nanomedicine 17:1409–1421
Article PubMed PubMed Central Google Scholar
Golla K, Cherukuvada B, Ahmed F, Kondapi AK (2012) Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. PLoS One. https://doi.org/10.1371/journal.pone.0051960
Article PubMed PubMed Central Google Scholar
Golla K, Bhaskar C, Ahmed F, Kondapi AK (2013) A target-specific oral formulation of doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer. J Cancer 4:644–652
Article PubMed PubMed Central Google Scholar
Kumari S, Kondapi AK (2017) Lactoferrin nanoparticle mediated targeted delivery of 5-fluorouracil for enhanced therapeutic efficacy. Int J Biol Macromol. https://doi.org/10.1016/j.ijbiomac.2016.10.110
Ahmed F, Kumari S, Kondapi AK (2018) Evaluation of antiproliferative activity, safety and biodistribution of oxaliplatin and 5-fluorouracil loaded lactoferrin nanoparticles for the management of colon adenocarcinoma: an in vitro and an in vivo study. Pharm Res. https://doi.org/10.1007/S11095-018-2457-7
Kumari S, Ahsan SM, Kumar JM, Kondapi AK, Rao NM (2017) Overcoming blood brain barrier with a dual purpose temozolomide loaded lactoferrin nanoparticles for combating glioma (SERP-17-12433). Sci Rep 7:1–13
Ahmed F, Ali MJ, Kondapi AK (2014) Carboplatin loaded protein nanoparticles exhibit improve anti-proliferative activity in retinoblastoma cells. Int J Biol Macromol 70:572–582
Article CAS PubMed Google Scholar
Narayana RVL, Jana P, Tomar N, Prabhu V, Nair RM, Manukonda R, Kaliki S, Coupland SE, Alexander J, Kalirai H, Kondapi AK, Vemuganti GK (2021) Carboplatin- and etoposide-loaded lactoferrin protein nanoparticles for targeting cancer stem cells in retinoblastoma in vitro. Investig Ophthalmol Vis Sci 62:13–13
Bannerji R, Rosenthal FM, Heston WDW, Fair WR, Gansbacher B, Gilboa E (1994) Immunotherapy of prostate cancer in the dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54:1760–1765
Athmakur H, Kondapi AK (2018) Carmustine loaded lactoferrin nanoparticles demonstrates an enhanced antiproliferative activity against glioblastoma in vitro. Int J Appl Pharm. https://doi.org/10.22159/ijap.2018v10i6.28004
Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. https://doi.org/10.1021/mp800051m
Article PubMed PubMed Central Google Scholar
Kumar P, Lakshmi YS, Bhaskar C, Golla K, Kondapi AK (2015) Improved safety, bioavailability and pharmacokinetics of zidovudine through lactoferrin nanoparticles during oral administration in rats. PLoS One. https://doi.org/10.1371/journal.pone.0140399
Article PubMed PubMed Central Google Scholar
Kumari S, Kondapi AK (2018) Receptor-mediated targeted delivery of DNA using lactoferrin nanoparticles. Int J Biol Macromol 108:401–407
Article CAS PubMed Google Scholar
Smirnov IM, Bailey K, Flowers CH, Garrigues NW, Wesselius LJ, Igor M (2022) Effects of TNF-α and IL-1 β on iron metabolism by A549 cells and influence on cytotoxicity. Am J Physiol Lung Cell Mol Physiol 277:L257–L263
Elfinger M, Maucksch C, Rudolph C (2007) Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials 28:3448–3455
Article CAS PubMed Google Scholar
Uyeturk U, Sarıcı H, Kın Tekce B, Eroglu M, Kemahlı E, Uyeturk U, Gucuk A (2014) Serum omentin level in patients with prostate cancer. Med Oncol 31:6–10
Fryczkowski M, Bułdak RJ, Hejmo T, Kukla M, Zwirska-Korczala K (2018) Circulating levels of omentin, leptin, VEGF, and HGF and their clinical relevance with PSA marker in prostate cancer. Dis Mark. https://doi.org/10.1155/2018/3852401
Chen Z, Tai Z, Gu F, Hu C, Zhu Q, Gao S (2016) Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy. Eur J Pharm Biopharm 107:130–141
Article CAS PubMed Google Scholar
Wang Q, Alshaker H, Böhler T, Srivats S, Chao Y, Cooper C, Pchejetski D (2017) Core shell lipid–polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer. Sci Rep 7:1–8
PubMed PubMed Central Google Scholar
Li LT, Jiang G, Chen Q, Zheng JN (2015) Predic Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep 11:1566–1572
留言 (0)